Anne Genevieve Marcelin

Summary

Country: France

Publications

  1. doi request reprint A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure
    Anne Genevieve Marcelin
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Univ Paris 06, INSERM U943, Paris, France
    Int J Antimicrob Agents 42:42-7. 2013
  2. doi request reprint Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens
    A G Marcelin
    Universite Pierre et Marie Curie Paris 6, UMR S 943, Paris F 75013, France
    J Antimicrob Chemother 67:1475-8. 2012
  3. ncbi request reprint Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen
    Anne Genevieve Marcelin
    AP HP, Pitie Salpetriere Hospital, Pierre et Marie Curie University, INSERM U943, Paris, France
    Antivir Ther 17:119-23. 2012
  4. ncbi request reprint Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease
    Anne Genevieve Marcelin
    Service de virologie UPRES EA 2387, Paris, France
    J Infect Dis 196:1163-6. 2007
  5. ncbi request reprint Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpftriere Hospital, AP HP, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 12:247-52. 2007
  6. pmc Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 52:3237-43. 2008
  7. ncbi request reprint [Resistance to protease inhibitors: the burden of mutations]
    A G Marcelin
    Service de Virologie, Hopital Pitie Salpetriere, 47, Boulevard de l Hopital, 75013 Paris, France
    Med Mal Infect 36:S198-205. 2006
  8. pmc Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 54:72-7. 2010
  9. ncbi request reprint Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma
    Anne Genevieve Marcelin
    UPMC Univ Paris 06, EA 2387, Paris, France
    AIDS 22:1677-9. 2008
  10. pmc Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 52:4251-7. 2008

Detail Information

Publications103 found, 100 shown here

  1. doi request reprint A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure
    Anne Genevieve Marcelin
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Univ Paris 06, INSERM U943, Paris, France
    Int J Antimicrob Agents 42:42-7. 2013
    ..RAL showed great potency in treatment-experienced patients. The number of new drugs associated with RAL was an important factor associated with VR. HIV-1 subtype and baseline integrase polymorphisms do not influence the RAL VR...
  2. doi request reprint Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens
    A G Marcelin
    Universite Pierre et Marie Curie Paris 6, UMR S 943, Paris F 75013, France
    J Antimicrob Chemother 67:1475-8. 2012
    ....
  3. ncbi request reprint Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen
    Anne Genevieve Marcelin
    AP HP, Pitie Salpetriere Hospital, Pierre et Marie Curie University, INSERM U943, Paris, France
    Antivir Ther 17:119-23. 2012
    ..The aim of this study was to characterize the mutations selected upon failure on etravirine (ETR)-containing regimen in non-nucleoside reverse transcriptase inhibitors (NNRTIs)-experienced HIV-infected patients and the associated factors...
  4. ncbi request reprint Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease
    Anne Genevieve Marcelin
    Service de virologie UPRES EA 2387, Paris, France
    J Infect Dis 196:1163-6. 2007
    ..63 log(10) copies/150,000 cells). Determining the KSHV-DNA level may be useful in diagnosing KSHV-associated disease and for following up patients with KS when the development of MCD or PEL is suspected...
  5. ncbi request reprint Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpftriere Hospital, AP HP, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 12:247-52. 2007
    ..To identify a genotypic score for resistance to saquinavir boosted with ritonavir (SQV/r; 1,000/100 mg twice daily)-based regimens in protease inhibitor (PI)-experienced patients...
  6. pmc Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 52:3237-43. 2008
    ....
  7. ncbi request reprint [Resistance to protease inhibitors: the burden of mutations]
    A G Marcelin
    Service de Virologie, Hopital Pitie Salpetriere, 47, Boulevard de l Hopital, 75013 Paris, France
    Med Mal Infect 36:S198-205. 2006
  8. pmc Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 54:72-7. 2010
    ..In conclusion, ETR was associated with high response rates in NNRTI-experienced patients in combination with other active drugs regardless of the therapeutic class used...
  9. ncbi request reprint Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma
    Anne Genevieve Marcelin
    UPMC Univ Paris 06, EA 2387, Paris, France
    AIDS 22:1677-9. 2008
    ..This result justifies measuring HIV-1 RNA in semen before the ART process and suggests that a residual risk of transmission has to be mentioned to the patients who would like to have unprotected sexual intercourse...
  10. pmc Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 52:4251-7. 2008
    ....
  11. ncbi request reprint [HIV drug resistance]
    Anne Genevieve Marcelin
    Service de Virologie, Hopital de la Pitie, 75651 Paris Cedex 13
    Rev Prat 56:978-86. 2006
    ..These tests are now widely used in developed countries and are recommended in case of therapeutic failure in treated patients and in case of recent infection in naive patients...
  12. pmc Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study
    Patricia Recordon-Pinson
    Laboratoire de Virologie, CHU de Bordeaux, Bordeaux Cedex, France
    Antimicrob Agents Chemother 54:3335-40. 2010
    ..The baseline weighted genotypic sensitivity score was associated with VR at month 6. There were strong arguments in favor of using genotypic coreceptor use assays for determining which patients would respond to CCR5 antagonist...
  13. doi request reprint Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients
    Diane Descamps
    AP HP, Groupe Hospitalier Bichat Claude Bernard and Université Denis Diderot Paris 7, Laboratoire de Virologie, Paris, France
    J Antimicrob Chemother 63:585-92. 2009
    ..The aim of the study was to identify a pattern of protease gene mutations associated with the virological response to darunavir/ritonavir-based regimens...
  14. ncbi request reprint Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097)
    Constance Delaugerre
    Department of Virology, Pitié Salpetrière Hospital Paris, Paris, France
    J Med Virol 77:345-50. 2005
    ..These results suggest that pharmacological enhancement might overcome viral resistance and that there is some benefit in adding the activity of several boosted-PIs to improve the response to a salvage regimen...
  15. ncbi request reprint Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali
    Anne Derache
    Department of Virology, Pitie Salpetriere Hospital, AP HP, EA 2387, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 12:123-9. 2007
    ..To determine the genetic diversity of HIV-1 reverse transcriptase (RT) and protease sequences and the presence of mutations linked to antiretroviral (ARV) resistance in treatment-naive, HIV-1-infected individuals living in Mali...
  16. ncbi request reprint Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals
    Claudine Duvivier
    Department of Infectious Diseases, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 8:603-9. 2003
    ..To evaluate the efficacy and tolerability of indinavir/ritonavir (IDV/RTV) 400/100 mg twice daily in combination with two nucleoside reverse transcriptase inhibitors in antiretroviral-naive patients...
  17. pmc Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    Antimicrob Agents Chemother 48:4687-92. 2004
    ....
  18. ncbi request reprint Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure
    Anne Genevieve Marcelin
    Department of Virology, Pitié Salpêtrière Hospital and University Paris VI Pierre et Marie Curie, Paris, France
    J Med Virol 72:162-5. 2004
    ....
  19. pmc Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro
    Isabelle Malet
    Laboratoire de Virologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
    Antimicrob Agents Chemother 52:1351-8. 2008
    ..These mutations led to strong impairment of enzymes in vitro in the absence of raltegravir: strand transfer activity was affected, and in some cases 3' processing was also impaired...
  20. pmc Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, INSERM EMI 0214, Bichat Claude Bernard Hospital, Paris, France
    Antimicrob Agents Chemother 47:594-600. 2003
    ....
  21. pmc Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine
    Constance Delaugerre
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    Antimicrob Agents Chemother 46:1586-8. 2002
    ....
  22. ncbi request reprint Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey
    Constance Delaugerre
    Department of Virology EA3620, Necker Hospital, Paris, France
    AIDS 21:1365-7. 2007
    ..In both cases, infection was caused by CCR5 viruses and no rapid clinical progression to AIDS after primary infection was observed...
  23. pmc Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir
    Sidonie Lambert-Niclot
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris 75013, France
    Antimicrob Agents Chemother 52:491-6. 2008
    ..TPV susceptibility does not seem to be affected by the selection of a DRV resistance mutation...
  24. ncbi request reprint Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission
    Constance Delaugerre
    Department of Virology EA2387 and Infectious Diseases, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 9:415-21. 2004
    ..To understand the virological mechanisms of 2-year persistence of multidrug-resistant virus without selective antiretroviral pressure in HIV-1-infected patients...
  25. ncbi request reprint Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma
    Amelie Guihot
    Laboratoire d Immunologie Cellulaire et Tissulaire du Pr Debre, INSERM UMR S 543, Batiment CERVI, Hopital Pitie Salpetriere, 47 bd de l Hopital, 75013, Paris, France
    J Infect Dis 194:1078-88. 2006
    ..We hypothesized that KS is linked to deficiencies in specific anti-HHV-8 T cell immunity...
  26. ncbi request reprint Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance
    Diane Descamps
    Laboratoire de Virologie, CHU Bichat Claude Bernard, Paris, France
    J Med Virol 78:153-60. 2006
    ..077). No errors were made by 19% of laboratories in 2002, compared to 42% in 2003. These results show the value of repeated external quality assessments...
  27. ncbi request reprint Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    J Med Virol 74:16-20. 2004
    ..There was no relation between the resistance pathways selected with either APV or ritonavir plasma minimal concentration, but higher APV plasma minimal concentration were associated with a lower rate of resistance mutations selection...
  28. doi request reprint Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases
    Isabelle Malet
    UPMC Universite Paris 06, Paris, France
    J Med Virol 80:754-61. 2008
    ..In conclusion, virological response to anti-integrase should be studied carefully, according to the subtype, in clinical trials...
  29. doi request reprint Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, 83 bvd de l Hôpital, 75013 Paris, France
    J Antimicrob Chemother 66:709-12. 2011
    ..Analyses of proviral HIV-DNA can provide information about the viral reservoir, because integrated DNA reflects both actively and latently infected cells...
  30. ncbi request reprint Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients
    Isabelle Malet
    Laboratoire de Virologie bâtiment CERVI, Hopital Pitie Salpetriere, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
    J Infect 54:367-74. 2007
    ..Moreover, we have evaluated associations between the Gag region sequence and the virological response to Protease Inhibitors (PI)...
  31. ncbi request reprint HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide
    Diane Descamps
    AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, Paris F 75018, France
    J Antimicrob Chemother 62:451-5. 2008
    ..We studied gp41 mutations associated with failing enfuvirtide salvage therapy...
  32. ncbi request reprint Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial)
    Constance Delaugerre
    Department of Virology EA2387, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 8:233-7. 2003
    ..To assess the effect of interleukin (IL)-2 combined with highly active antiretroviral therapy (HAART) on HIV-1 pro-viral DNA quantification in HIV-1-infected patients with CD4<200/mm3...
  33. ncbi request reprint Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors
    Benedicte Roquebert
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    AIDS 20:287-9. 2006
    ..These minor species, not detected by standard genotype, may influence PI susceptibility...
  34. ncbi request reprint Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial
    Vincent Calvez
    Department of Virology and Infectious Diseases and Pitie Salpetrière Hospital, Paris, France
    Antivir Ther 7:211-8. 2002
    ....
  35. ncbi request reprint Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    J Med Virol 76:297-301. 2005
    ..The K65R mutation can emerge even with TAMs or L74V. No obvious impact was shown on the TAMs or other NRTI mutations, although a trend towards emergence of some particular mutations was observed...
  36. doi request reprint Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy
    Sidonie Lambert-Niclot
    AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University, Paris, France
    J Antimicrob Chemother 67:1470-4. 2012
    ....
  37. doi request reprint Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists
    Cathia Soulie
    Universite Pierre et Marie Curie Paris 6, UMR S 943 Paris, F 75013, France
    J Antimicrob Chemother 65:749-51. 2010
    ..We aimed to analyse HIV-1 tropism using proviral DNA sequencing and the associated factors, in a group of patients on antiretroviral (ARV) treatment with an undetectable viral load in plasma...
  38. ncbi request reprint Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug
    Marc Wirden
    Department of Virology, AP HP, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris, France
    J Antimicrob Chemother 64:1087-90. 2009
    ..We determined whether raltegravir retains residual antiretroviral activity in vivo against viruses harbouring raltegravir mutations, and thus whether the drug can contribute to the subsequent regimen...
  39. ncbi request reprint HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART
    Cathia Soulie
    Department of Virology EA2387, Pitie Salpetriere Hospital, University Pierre et Marie Curie, Paris, France
    AIDS 21:2243-5. 2007
    ..This suggests that CCR5 antagonist activity should not be compromised in patients harbouring R5 viruses before starting HAART...
  40. pmc Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes
    Almoustapha Issiaka Maiga
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC University Paris 06, INSERM U943, Paris, France
    Antimicrob Agents Chemother 54:728-33. 2010
    ..However, the transmission of drug-resistant viruses with Y181C in a non-B genetic background has a potential for impact on ETR susceptibility...
  41. ncbi request reprint Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 11:693-9. 2006
    ..To determine the potential impact of reverse transcriptase (RT) mutations, other than those currently known to confer nucleoside reverse transcriptase inhibitors (NRTIs) resistance, on the virological response to didanosine (ddl)...
  42. pmc Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, 75013 Paris, France
    Antimicrob Agents Chemother 50:2553-6. 2006
    ..L74I was strongly associated with T215F, K70R, and V75M/S/T/A mutations and increased with the number of thymidine analog mutations. It seemed to be linked to the use of abacavir or efavirenz...
  43. ncbi request reprint Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients
    Fabienne Caby
    Service des Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Scand J Infect Dis 42:527-32. 2010
    ..If persistent low viraemia is observed over more than 48 weeks without the emergence of resistance, RAL should never be given as functional monotherapy, as it is associated with a maximal risk of VF and the emergence of RAL resistance...
  44. doi request reprint Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010
    Charlotte Charpentier
    Laboratoire de Virologie, Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Bichat Claude Bernard, HUPNVS, Universite Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, EA4409, 75018 Paris, France
    J Antimicrob Chemother 68:2197-8. 2013
    ..To assess the prevalence of the K65R, K103N and M184V/I resistance mutations in the reverse transcriptase (RT) region in HIV-1-infected patients failing antiretroviral-based regimens between the years 2005 and 2010...
  45. doi request reprint Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study
    Lambert Assoumou
    INSERM, U 943, Paris, France
    J Antimicrob Chemother 68:1400-5. 2013
    ..Surveillance of HIV-1 drug resistance in treated patients with plasma viral load (VL) >50 copies/mL...
  46. ncbi request reprint Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial
    Jean Michel Molina
    Department of Infectious Diseases, Saint Louis Hospital, Paris, France
    J Infect Dis 191:840-7. 2005
    ..The antiviral efficacy of didanosine in patients experiencing virological failure is not well known...
  47. pmc Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs
    Marc Wirden
    Department of Virology, Pitié Salpêtrière Hospital Department of Pharmacology, Bichat Hospital, Paris, France
    J Clin Microbiol 41:2713-5. 2003
    ..These data suggest that these compounds have lost all of their in vivo antiviral activity in such cases...
  48. pmc Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy
    Marc Wirden
    Department of Virology, INSERM EMI 0214, Pitie Salpetriere Hospital, Paris, France
    Antimicrob Agents Chemother 48:644-7. 2004
    ....
  49. ncbi request reprint Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice
    Sidonie Lambert-Niclot
    AP HP, Pitie Salpetriere Hospital, INSERM U943 and Pierre et Marie Curie University, Paris, France
    J Antimicrob Chemother 67:2487-93. 2012
    ..Virological failures of lopinavir/ritonavir and their effects on the resistance to protease inhibitors and reverse transcriptase inhibitors were evaluated in protease inhibitor-experienced patients...
  50. pmc Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks
    Sidonie Lambert-Niclot
    AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University Paris, Paris, France
    PLoS ONE 7:e41390. 2012
    ..Our objectives were to study the impact of 96 weeks of Darunavir/ritonavir monotherapy versus a triple standard combination on the HIV-1 blood reservoir and factors associated with HIV-1 plasma DNA at baseline in MONOI trial sub-study...
  51. doi request reprint The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype
    Isabelle Malet
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Universite Paris 06, INSERM U943, Paris, France
    J Antimicrob Chemother 66:2827-30. 2011
    ..The aim of this study was to explore resistance pathways preferably used by CRF02_AG viruses compared with subtype B...
  52. doi request reprint Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease
    Sidonie Lambert-Niclot
    UPMC Univ Paris 06, EA 2387, F 75005, Paris, France
    J Antimicrob Chemother 62:905-8. 2008
    ..To search for genetic factors in the protease and gag regions (NC-p1/TFP-p6/p6pol) involved in selection of darunavir resistance mutations...
  53. doi request reprint Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients
    Isabelle Malet
    UPMC Univ Paris 06, F 75005 Paris, France
    J Antimicrob Chemother 63:795-804. 2009
    ..The objective of this study was to characterize the dynamics of HIV-1 quasispecies variant populations in patients who failed to respond to raltegravir treatment...
  54. ncbi request reprint HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen
    Anne Genevieve Marcelin
    Pitie Salpetriere Hospital, Paris, France
    AIDS 21:2341-3. 2007
    ..This highlights the importance of the accessibility of HIV-RNA assays for monitoring treated patients in resource-poor countries to detect early virological failure in order to preserve future therapeutic options...
  55. pmc Clinically relevant genotype interpretation of resistance to didanosine
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 49:1739-44. 2005
    ..In conclusion, we developed and validated a genotypic score, taking into account mutations negatively and positively impacting the virologic response to ddI...
  56. ncbi request reprint Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20
    Anne Genevieve Marcelin
    Pitie Salpetriere Hospital, Paris, France
    AIDS 18:1340-2. 2004
    ..Our results suggest that only HR-1 sequencing is necessary to characterize resistance to T-20, and that HR-2 domain sequencing is probably not required...
  57. ncbi request reprint Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients
    Benedicte Roquebert
    Department of Virology, Pitié Salpêtrière Hospital and UPRES EA 2387, Universite Pierre et Marie Curie, Paris, France
    J Med Virol 79:207-11. 2007
    ..Mutations at position K558 were also associated with the number of thymidine analog mutations (TAMs). These results suggest that these mutations could play a role in NRTI resistance...
  58. doi request reprint E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure
    Slim Fourati
    Université Pierre et Marie Curie Paris, Groupe Hospitalier Pitie Salpetriere, Laboratoire de Virologie, Paris, France
    AIDS 26:1619-24. 2012
    ..We show here that APOBEC3 proteins play a role in the emergence of these drug resistance mutations...
  59. doi request reprint HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis
    Cathia Soulie
    Universite Pierre et Marie Curie Paris 6, UMR S 943, France
    AIDS 24:2412-4. 2010
    ..Conversely, a high viral genetic diversity was associated with an undetectable HIV RNA in plasma and low-balanced CPE, which is in favour of an autonomous replication in the central nervous system...
  60. ncbi request reprint Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + n
    Cathia Soulie
    Université Pierre et Marie Curie Paris, UMR S 943, INSERM, U943, Paris, France
    AIDS 23:1605-8. 2009
    ..The NNRTI + protease inhibitor strategy should not be recommended as an antiretroviral first-line regimen, particularly in patients with high viral load at baseline...
  61. ncbi request reprint Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes
    Almoustapha Issiaka Maiga
    Department of Virology, Pitie Salpetriere Hospital, AP HP, EA 2387, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 14:123-9. 2009
    ..The genetic barrier for IN inhibitor resistance was compared between HIV-1 subtype B and HIV-1 subtype CRF02_AG, which is highly prevalent in West Africa and becoming more frequent in developed countries...
  62. doi request reprint Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients
    Isabelle Malet
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Universite Paris 06, INSERM U943, Paris, France
    J Antimicrob Chemother 66:1481-3. 2011
    ....
  63. pmc Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy
    Sidonie Lambert-Niclot
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris, France
    Antimicrob Agents Chemother 54:4910-3. 2010
    ..The median darunavir seminal plasma concentration was close to the blood plasma free fraction, demonstrating a good penetration of darunavir into the male genital tract...
  64. doi request reprint Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy
    Sidonie Lambert-Niclot
    Department of Virology and Infectious Diseases, AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University, Paris, France
    J Infect Dis 204:1211-6. 2011
    ..Our objective was to determine virological and clinical characteristics associated with virological failure in human immunodeficiency virus (HIV)-infected patients switching to darunavir/ritonavir (DRV/r) monotherapy...
  65. ncbi request reprint Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial
    Christophe Piketty
    Department of Immunology, Hôpital Georges Pompidou, Assistance Publique Hopitaux de Paris, Paris, France
    Antivir Ther 11:213-21. 2006
    ..Ritonavir (RTV)-boosted atazanavir (ATV) and tenofovir disoproxil fumarate (TDF-DF) are promising in highly experienced patients because of their pharmacokinetic profile, activity, safety and resistance properties...
  66. doi request reprint Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml
    Stéphanie Haïm-Boukobza
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Univ Paris, Paris, France
    AIDS 25:341-4. 2011
    ..To compare the level of HIV-1 residual viremia, defined by a viral load below 50 copies/ml in patients receiving a tenofovir/emtricitabine and nevirapine (NVP) or efavirenz (EFV)-containing regimen...
  67. doi request reprint Risk factors for raltegravir resistance development in clinical practice
    Isabelle Malet
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Université Pierre et Marie Curie, INSERM U943, Paris, France
    J Antimicrob Chemother 67:2494-500. 2012
    ..To investigate the best conditions of raltegravir use to avoid the selection of resistance mutations in the three main genetic pathways: 148, 155 and 143...
  68. ncbi request reprint Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients
    Isabelle Malet
    Laboratoire de Virologie, Universite Pierre et Marie Curie Paris 6, France
    AIDS 21:871-3. 2007
    ..Overall, the CA-SP1 cleavage site was highly conserved in PI pre-treated patients and only one patient showed an L231M mutation. The impact of this mutation should be further addressed in vivo...
  69. doi request reprint E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations
    Slim Fourati
    Universite Pierre et Marie Curie, Paris, France
    Antiviral Res 93:167-74. 2012
    ..This process may play a role in the kinetics of appearance of drug resistance mutations under antiretroviral treatment...
  70. pmc Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy
    Jade Ghosn
    AP HP, Department of Infectious Diseases, Pitie Salpetriere Hospital, 47 Boulevard de l Hopital, 75013 Paris, France
    Antimicrob Agents Chemother 52:1542-4. 2008
    ..At delivery, 26 of 28 women on indinavir-ritonavir had HIV RNA levels of <200 copies/ml. No infant was HIV infected. These data are encouraging for the use of this combination for prevention of mother-to-child transmission of HIV...
  71. doi request reprint Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    AIDS 23:95-9. 2009
    ..This lack of knowledge has led to contradictory and confusing attitudes to L74I; although this mutation is not listed by the International AIDS Society - USA, it is increasingly included in several resistance algorithms...
  72. ncbi request reprint Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006
    Anne Derache
    UPMC Univ Paris 06, EA2387, 4 place Jussieu, F 75005 Paris, France
    J Antimicrob Chemother 62:456-63. 2008
    ..To describe HIV-1 variants circulating in Mali and to estimate the rate of transmission of HIV-1 drug resistance in 2006...
  73. ncbi request reprint Rituximab therapy for HIV-associated Castleman disease
    Anne Genevieve Marcelin
    Department of Virology, UPRES 2387, Pitie Salpetriere Hospital, Paris, France
    Blood 102:2786-8. 2003
    ..Our preliminary results suggest that rituximab may be effective in controlling Castleman disease in a subset of patients, although it may exacerbate concomitant Kaposi sarcoma...
  74. pmc Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 49:1720-6. 2005
    ..Therapeutic drug monitoring for patients treated by lopinavir-ritonavir would likely be most useful in patients with substantially resistant viruses...
  75. doi request reprint Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy
    Amelie Guihot
    UPMC Univ Paris 06, INSERM, UMR945, AP HP, Laboratoire d Immunologie Cellulaire et Tissulaire, Hopital Pitie Salpetriere, Paris, France
    AIDS 24:614-7. 2010
    ..Long-term and efficient antiretroviral therapy provides continuous benefits both on the immune system and on the HIV reservoirs...
  76. doi request reprint Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy
    Ana Canestri
    Hopital Pitie Salpetriere, Paris, France
    Clin Infect Dis 50:773-8. 2010
    ..We report data on 11 patients with neurological symptoms and human immunodeficiency virus (HIV) cerebrospinal fluid (CSF) viremia contrasting with suppressed plasma HIV RNA during receipt of combined antiretroviral therapy...
  77. pmc Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir
    Lucile Larrouy
    AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, 75018 Paris, France
    Antimicrob Agents Chemother 55:1754-7. 2011
    ..028). Our results suggest that a specific gag CSM might have a role on protease inhibitor susceptibility in an inhibitor-specific manner...
  78. doi request reprint Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients
    Cathia Soulie
    UMPC Université Paris 06, Paris, France
    AIDS 22:2212-4. 2008
    ..The V3 loop region was rather polymorphic, and 7.3% of patients showed viruses with combinations of mutations in V3 loop previously described to be involved in maraviroc resistance, a licensed CCR5 antagonist...
  79. ncbi request reprint Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study
    Dominique Costagliola
    INSERM, Unité Mixte de Recherche UMR S 720, Universite Pierre et Marie Curie Paris 6, Paris, France
    J Acquir Immune Defic Syndr 46:12-8. 2007
    ..Surveillance of HIV-1 drug resistance in antiretroviral-treated patients is important from the public health perspective of the spread of resistance and to evaluate the proportion of patients for whom new drugs are needed...
  80. ncbi request reprint High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease
    Jean Gabarre
    Service d Hematologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France
    Haematologica 89:1100-8. 2004
    ....
  81. ncbi request reprint Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France
    Diane Descamps
    Laboratoire de Virologie, AP HP Groupe hospitalier Bichat Claude Bernard and EA 4409 Université Paris Diderot Paris 7, Paris, France
    J Antimicrob Chemother 65:2620-7. 2010
    ..To estimate the prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-1-infected patients in France...
  82. ncbi request reprint Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection
    Philippe Flandre
    Unité INSERM U720, BP 335 75625, Paris, France
    J Infect Dis 195:392-8. 2007
    ..We investigated the relationship between human immunodeficiency virus (HIV) phenotypic susceptibility to didanosine and the antiviral activity of didanosine (ddI) in the JAGUAR study...
  83. ncbi request reprint Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients
    Ana Canestri
    AP HP, Hopital Pitie Salpetriere, Service des Maladies Infectieuses et Tropicales, Paris, France
    AIDS 24:2887-9. 2010
    ..Seroprotection, seroconversion, and geometric mean titer ratio of specific antibody titers did not differ between groups. These results suggest that maraviroc does not significantly affect the immune response to this adjuvanted vaccine...
  84. ncbi request reprint Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1
    Yves Benhamou
    Groupe Hospitalier Pitie Salpetriere, Service de d Hépato Gastroentérologie, Paris, France
    J Hepatol 44:62-7. 2006
    ..Adefovir dipivoxil (10 mg once-daily) was added to antiretroviral therapy including lamivudine in 35 HIV/HBV co-infected patients...
  85. ncbi request reprint Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    AIDS 19:630-2. 2005
    ..We found no clone bearing both K65R and L74V substitutions. Moreover, the S68G and V75I mutations are not necessarily linked with K65R, and could thus have their own resistance effect...
  86. doi request reprint HIV-1 or hepatitis C chronic infection in serodiscordant infertile couples has no impact on infertility treatment outcome
    Nadia Prisant
    UF de biologie de la reproduction, Groupe Hospitalier Pitie Salpetriere, 75013 Paris, France
    Fertil Steril 93:1020-3. 2010
    ..Clinical pregnancy rate for HIV-1 or HCV infertile serodiscordant couples was not significantly different from that for seronegative controls...
  87. doi request reprint Resistance to novel drug classes
    Anne Genevieve Marcelin
    UMR INSERM UPMC, Université Pierre et Marie Curie U 943, AP HP, Hopital Pitie Salpetriere, Laboratoire de Virologie, Paris, France
    Curr Opin HIV AIDS 4:531-7. 2009
    ..Understanding the mechanisms that underlie resistance development to novel drugs is essential to a better clinical management of resistant viruses and to prevent further resistance development and spread...
  88. doi request reprint Effect of antiretroviral drugs on the quality of semen
    Sidonie Lambert-Niclot
    UPMC Pierre et Marie Curie University, Paris, France
    J Med Virol 83:1391-4. 2011
    ..NRTIs and PIs were not associated with any semen changes. Nevirapine was associated with a better quality of semen versus efavirenz. It would be of interest to validate, improve and test our penetration score in a prospective study...
  89. ncbi request reprint Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients
    Anne Genevieve Marcelin
    Department of Virology UPRES 2387, Pitie Salpetriere Hospital, Paris, France
    Liver Transpl 10:295-300. 2004
    ....
  90. pmc Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes
    M Wirden
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    J Clin Microbiol 47:1543-5. 2009
    ..The differences exceeded 0.5 log for about 20% of samples and 1 log for 3%, with higher values always from the Abbott assay in the latter cases...
  91. ncbi request reprint Outcome of kidney transplant recipients with previous human herpesvirus-8 infection
    C Frances
    Department of Internal Medicine, Hopital Pitie Salpetriere, Paris, France
    Transplantation 69:1776-9. 2000
    ..The aim of this monocentric study was to determine the prevalence of HHV-8-seropositive patients at the time of transplantation and to identify the main clinical events of these HHV-8+ recipients...
  92. ncbi request reprint The impact of preexisting or acquired Kaposi sarcoma herpesvirus infection in kidney transplant recipients on morbidity and survival
    C Frances
    Department of Dermatology Allergology, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie, Hopital Tenon, Paris, France
    Am J Transplant 9:2580-6. 2009
    ..In conclusion, although kidney recipients should be aware of the additional risk of KSHV morbidity, KSHV+ recipients should not be systematically excluded from kidney transplantation...
  93. ncbi request reprint Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect
    Marion Malphettes
    Departement d Immunologie, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, Paris, France
    Clin Infect Dis 49:1329-38. 2009
    ..Common variable immunodeficiency (CVID) is a primary immune deficiency defined by defective antibody production. In most series, a small proportion of patients present with opportunistic infections (OIs)...
  94. doi request reprint National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation
    C Delaugerre
    CHU Ambroise Pare, Boulogne, France
    J Med Virol 80:762-5. 2008
    ..In conclusion, the K70E mutation could be an alternative pathway of TDF resistance, but as the K65R mutation, other NRTI as ABC, ddI, and 3TC could be also associated with the K70E selection...
  95. doi request reprint Detection of human herpesviruses HHV-6, HHV-7 and HHV-8 in whole blood by real-time PCR using the new CMV, HHV-6, 7, 8 R-gene kit
    C Deback
    Service de Virologie du CERVI, UPRES EA 2387, Universite Pierre et Marie Curie Paris 6, Groupe Hospitalier Pitié Salpêtrière AP HP, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    J Virol Methods 149:285-91. 2008
    ..7% (n=96) in A and B, respectively. These results demonstrate that the new commercial CMV HHV-6, 7, 8 R-gene kit was an efficient and reliable tool for the diagnosis of herpesvirus 6, 7, 8 infections...
  96. doi request reprint Comparison of two genotypic algorithms to determine HIV-1 tropism
    C Soulie
    Department of Virology, Pitie Salpetriere Hospital, Pierre et Marie Curie Paris 6 University, 47 83 Bd de l Hopital, 75651 Paris Cedex 13, France
    HIV Med 9:1-5. 2008
    ..A comparison of the position-specific scoring matrices (PSSM) and Geno2pheno algorithms based on the V3 loop gp120 sequences and previously described to be correlated to the R5 or X4 phenotype was carried out...
  97. doi request reprint Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients
    S Lambert-Niclot
    INSERM U943, AP HP, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, Paris, France
    HIV Med 11:666-9. 2010
    ..The objective of this study was to explore the virological response when combination atazanavir/ritonavir was administered to treatment-naı¨ve patients...
  98. ncbi request reprint GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy
    P Bossi
    Department of Infectious Diseases, Pitie Salpetriere Hospital, 47 83 boulevard de l Hopital, 75013 Paris, France
    HIV Med 5:352-9. 2004
    ..To evaluate the benefits of therapeutic drug monitoring (TDM) in association with genotypic resistance testing and expert advice to optimize therapy in multiexperienced patients infected with HIV-1...
  99. ncbi request reprint Clinical features and contribution of virological findings to the management of Kaposi sarcoma in organ-allograft recipients
    S Barete
    Service de Virologie CERVI, Groupe Hospitalier Pitie Salpetriere, 83, Boulevard de l Hôpital 75651, Paris, Cedex 13, France
    Arch Dermatol 136:1452-8. 2000
    ..To describe the clinical features of Kaposi sarcoma (KS) in organ-allograft recipients and to determine the contribution of human herpesvirus 8 (HHV-8) investigations to the management of KS...
  100. doi request reprint Stability of HIV RNA in plasma specimens stored at different temperatures
    B Amellal
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    HIV Med 9:790-3. 2008
    ..Samples from remote areas are transported under suboptimal conditions. Here we evaluated HIV-1 RNA stability in plasma stored at different temperatures for 1 week...
  101. ncbi request reprint KSHV after an organ transplant: should we screen?
    A G Marcelin
    Department of Virology, Pitie Salpetriere Hospital, Pierre et Marie Curie University, UPRES EA 2387, 83 bd de l hopital, 75013 Paris, France
    Curr Top Microbiol Immunol 312:245-62. 2007
    ....